FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2167282010> ?p ?o ?g. }

• W2167282010 endingPage "574" @default.
• W2167282010 startingPage "568" @default.
• W2167282010 abstract "To improve outcomes of patients with Richter syndrome (RS) and relapsed/refractory chronic lymphocytic leukemia (CLL), we modified the OFAR1 regimen (oxaliplatin and cytarabine doses of the oxaliplatin, fludarabine, cytarabine, and rituximab) for this phase I-II study (OFAR2).OFAR2 consisted of oxaliplatin at 30 mg/m(2) on days 1 to 4, fludarabine at 30 mg/m(2), cytarabine at 0.5 g/m(2), rituximab at 375 mg/m(2) on day 3, and pegfilgrastim at 6 mg on day 6. Fludarabine and cytarabine were given on days 2 and 3 (cohort 1), days 2 to 4 (cohort 2), or days 2 to 5 (cohort 3) every 4 weeks. Phase II followed the 3 + 3 design of phase I.The 102 patients (CLL, 67; RS, 35) treated had heavily pretreated high-risk disease. Twelve patients were treated in phase I; cohort 2 was the phase II recommended dose. The most common toxicities were hematologic. Response rates (phase II) were 38.7% for RS (complete response [CR], 6.5%) and 50.8% for relapsed/refractory CLL (CR, 4.6%). The median survival durations were 6.6 (RS) and 20.6 (CLL) months. Among 9 patients who underwent allogeneic stem cell transplantation (SCT) as post-remission therapy, none has died (median follow-up, 15.9 months).OFAR2 had significant antileukemic activity in RS and relapsed/refractory CLL. Patients undergoing SCT as post-remission therapy had favorable outcomes." @default.
• W2167282010 created "2016-06-24" @default.
• W2167282010 creator A5006104041 @default.
• W2167282010 creator A5027575595 @default.
• W2167282010 creator A5030359399 @default.
• W2167282010 creator A5036290225 @default.
• W2167282010 creator A5036828560 @default.
• W2167282010 creator A5040146877 @default.
• W2167282010 creator A5044840107 @default.
• W2167282010 creator A5084379902 @default.
• W2167282010 creator A5085393928 @default.
• W2167282010 creator A5089428686 @default.
• W2167282010 date "2013-10-01" @default.
• W2167282010 modified "2023-10-17" @default.
• W2167282010 title "Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome" @default.
• W2167282010 cites W1591193872 @default.
• W2167282010 cites W1880372716 @default.
• W2167282010 cites W1881397173 @default.
• W2167282010 cites W1912693401 @default.
• W2167282010 cites W1963690972 @default.
• W2167282010 cites W1985871504 @default.
• W2167282010 cites W2032171886 @default.
• W2167282010 cites W2039906080 @default.
• W2167282010 cites W2045741361 @default.
• W2167282010 cites W2047259755 @default.
• W2167282010 cites W2051667118 @default.
• W2167282010 cites W2058015212 @default.
• W2167282010 cites W2082312121 @default.
• W2167282010 cites W2117964879 @default.
• W2167282010 cites W2122567519 @default.
• W2167282010 cites W2130081091 @default.
• W2167282010 cites W2140402067 @default.
• W2167282010 cites W2255094305 @default.
• W2167282010 cites W2416330504 @default.
• W2167282010 cites W4241762497 @default.
• W2167282010 cites W60865865 @default.
• W2167282010 doi "https://doi.org/10.1016/j.clml.2013.03.012" @default.
• W2167282010 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4180513" @default.
• W2167282010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23810245" @default.
• W2167282010 hasPublicationYear "2013" @default.
• W2167282010 type Work @default.
• W2167282010 sameAs 2167282010 @default.
• W2167282010 citedByCount "67" @default.
• W2167282010 countsByYear W21672820102013 @default.
• W2167282010 countsByYear W21672820102014 @default.
• W2167282010 countsByYear W21672820102015 @default.
• W2167282010 countsByYear W21672820102016 @default.
• W2167282010 countsByYear W21672820102017 @default.
• W2167282010 countsByYear W21672820102018 @default.
• W2167282010 countsByYear W21672820102019 @default.
• W2167282010 countsByYear W21672820102020 @default.
• W2167282010 countsByYear W21672820102021 @default.
• W2167282010 countsByYear W21672820102022 @default.
• W2167282010 countsByYear W21672820102023 @default.
• W2167282010 crossrefType "journal-article" @default.
• W2167282010 hasAuthorship W2167282010A5006104041 @default.
• W2167282010 hasAuthorship W2167282010A5027575595 @default.
• W2167282010 hasAuthorship W2167282010A5030359399 @default.
• W2167282010 hasAuthorship W2167282010A5036290225 @default.
• W2167282010 hasAuthorship W2167282010A5036828560 @default.
• W2167282010 hasAuthorship W2167282010A5040146877 @default.
• W2167282010 hasAuthorship W2167282010A5044840107 @default.
• W2167282010 hasAuthorship W2167282010A5084379902 @default.
• W2167282010 hasAuthorship W2167282010A5085393928 @default.
• W2167282010 hasAuthorship W2167282010A5089428686 @default.
• W2167282010 hasBestOaLocation W21672820102 @default.
• W2167282010 hasConcept C121332964 @default.
• W2167282010 hasConcept C121608353 @default.
• W2167282010 hasConcept C126322002 @default.
• W2167282010 hasConcept C141071460 @default.
• W2167282010 hasConcept C142424586 @default.
• W2167282010 hasConcept C143998085 @default.
• W2167282010 hasConcept C2776694085 @default.
• W2167282010 hasConcept C2776755627 @default.
• W2167282010 hasConcept C2777938653 @default.
• W2167282010 hasConcept C2778041864 @default.
• W2167282010 hasConcept C2778461978 @default.
• W2167282010 hasConcept C2779263901 @default.
• W2167282010 hasConcept C2779338263 @default.
• W2167282010 hasConcept C2780653079 @default.
• W2167282010 hasConcept C2780962732 @default.
• W2167282010 hasConcept C2781413609 @default.
• W2167282010 hasConcept C526805850 @default.
• W2167282010 hasConcept C71924100 @default.
• W2167282010 hasConcept C72563966 @default.
• W2167282010 hasConcept C87355193 @default.
• W2167282010 hasConcept C90924648 @default.
• W2167282010 hasConceptScore W2167282010C121332964 @default.
• W2167282010 hasConceptScore W2167282010C121608353 @default.
• W2167282010 hasConceptScore W2167282010C126322002 @default.
• W2167282010 hasConceptScore W2167282010C141071460 @default.
• W2167282010 hasConceptScore W2167282010C142424586 @default.
• W2167282010 hasConceptScore W2167282010C143998085 @default.
• W2167282010 hasConceptScore W2167282010C2776694085 @default.
• W2167282010 hasConceptScore W2167282010C2776755627 @default.
• W2167282010 hasConceptScore W2167282010C2777938653 @default.
• W2167282010 hasConceptScore W2167282010C2778041864 @default.
• W2167282010 hasConceptScore W2167282010C2778461978 @default.

• next